Pharma channel feed

Vi­a­tris and oth­ers be­come lat­est tar­gets of No­var­tis' En­tresto patent lit­i­ga­tion

3 years ago
Law

Up­dat­ed: Con­t­a­m­i­na­tion is­sues lead to FDA warn­ing let­ter for South Car­oli­na man­u­fac­tur­ing fa­cil­i­ty

3 years ago
FDA+
Manufacturing

What is No­var­tis with­out San­doz? Vas Narasimhan is 'pa­tien­t' as new com­pa­ny takes form

3 years ago

Au­rinia ‘can­did’ cam­paign en­cour­ages lu­pus nephri­tis pa­tients to stay cur­rent on doc­tor check­ups

3 years ago
Marketing

As­traZeneca's block­buster Fasen­ra fails on one of two PhI­II eosinophilic esophagi­tis tri­al end­points

3 years ago
R&D

FDA ap­proves J&J's BC­MA-tar­get­ed bis­pe­cif­ic for mul­ti­ple myelo­ma

3 years ago
FDA+

FDA rais­es safe­ty ques­tions with GSK's po­ten­tial CKD drug ahead of ad­comm

3 years ago
FDA+

Mar­ket­ingRx roundup: Pfiz­er bows Sea­son 2 of ‘Sci­ence Will Win’ pod­cast; Gilead’s Kite spon­sors can­cer light up nights

3 years ago
Marketing

The med­ical meta­verse is al­ready here, but what does that mean for phar­ma?

3 years ago
Marketing

GSK CEO Em­ma Walm­s­ley trig­gers ex­ec­u­tive team re­vamp as vac­cines chief Con­nor ex­its

3 years ago
People

Bio­gen's Q3 rev­enue de­clines 10% as fo­cus shifts to new Alzheimer's and ALS drug can­di­dates

3 years ago

Ex-Genen­tech sci­en­tist sen­tenced to six months in prison for steal­ing trade se­crets

3 years ago
People
Law

FDA in­spec­tion at Catal­ent’s Bel­gium fa­cil­i­ty un­cov­ers da­ta, equip­ment and oth­er QC is­sues

3 years ago
FDA+
Manufacturing

Phar­ma lob­by­ing head­ed for record-break­ing 2022, non­prof­it says

3 years ago

Re­gen­eron, Bay­er's Eylea nabs six months of pe­di­atric ex­clu­siv­i­ty as com­pe­ti­tion waits to en­ter the mar­ket

3 years ago
FDA+

Genen­tech's newest ad cam­paign calls out the sys­temic racism fu­el­ing US health in­equities

3 years ago
Marketing

Pfiz­er to make an al­most $1B in­vest­ment in its Dublin man­u­fac­tur­ing fa­cil­i­ty — re­port

3 years ago
Manufacturing

Up­dat­ed: Af­ter long slog, As­traZeneca fi­nal­ly gets CT­LA-4 drug over fin­ish line

3 years ago
FDA+

Roche is­sues vol­un­tary re­call for Susvi­mo over man­u­fac­tur­ing is­sue

3 years ago
Manufacturing

Will feds re­clas­si­fy 'mag­ic mush­room' ther­a­pies? Seat­tle doc­tor ramps up court bat­tle

3 years ago
Law

Ha­le­on draws at­ten­tion to un­paid sick days and lost wages in Ther­aflu cam­paign

3 years ago
Marketing

Rise 'til we fall: Phar­ma ad spend­ing still on the way up, even as most oth­er cat­e­gories drop

3 years ago
Marketing

J&J plans to cut 64 jobs at New York plant in new year

3 years ago
People

New in­dus­try re­port sug­gests UK clin­i­cal tri­al re­search re­cruit­ment is in mas­sive de­cline

3 years ago
R&D
First page Previous page 165166167168169170171 Next page Last page
A service from the Financial Times